Amneal Pharmaceuticals, Inc. (AMRX)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch AMRX
See up to 3 months of AMRX. The 7-day demo opens the 1M and 3M ranges and puts AMRX on your watchlist.
Start 7-day demoLatest AMRX insider trades
About Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. files with the SEC under CIK 0001723128 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
AMRX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 4 | 413,016 | $7.22M |
| Grant or award | 4 | 25,810,569 | |
| Option exercise | 3 | 209,463 | |
AMRX insider transactions (Form 4)
4251 Form 4 filings on record, the earliest from Nov 19, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Chirag K. Patel - Officer | Grant or award | Restricted Stock Units | 190,632 | $0.00 | - | |
| Chirag K. Patel - Officer | Grant or award | Performance-Based Restricted Stock Units | 354,031 | $0.00 | - | |
| Nikita Shah - Officer | Grant or award | Restricted Stock Units | 65,359 | $0.00 | - | |
| Nikita Shah - Officer | Grant or award | Performance-Based Restricted Stock Units | 65,359 | $0.00 | - | |
 Tasos Konidaris - Officer | Grant or award | Restricted Stock Units | 72,622 | $0.00 | - | |
| Tasos Konidaris - Officer | Grant or award | Performance-Based Restricted Stock Units | 72,622 | $0.00 | - | |
| Jason B. Daly - Officer | Grant or award | Restricted Stock Units | 65,359 | $0.00 | - | |
| Jason B. Daly - Officer | Grant or award | Performance-Based Restricted Stock Units | 65,359 | $0.00 | - | |
 Andrew S. Boyer - Officer | Grant or award | Restricted Stock Units | 65,359 | $0.00 | - | |
| Andrew S. Boyer - Officer | Grant or award | Performance-Based Restricted Stock Units | 65,359 | $0.00 | - | |
| Ted C. Nark - Director | Open-market sale | Class A Common Stock | 50,000 | $11.72 footnote F1 | $586K | |
| ||||||
| Nikita Shah - Officer | Option exercise | Stock Option (Right to Buy) | 95,525 | $0.00 | - | |
| Nikita Shah - Officer | Option exercise | Class A Common Stock | 36,331 | $2.75 | $100K | |
| Nikita Shah - Officer | Option exercise | Class A Common Stock | 95,525 | $2.75 | $263K | |
| Nikita Shah - Officer | Open-market sale | Class A Common Stock | 131,856 | $11.92 footnote F1 | $1.57M | |
| Nikita Shah - Officer | Option exercise | Stock Option (Right to Buy) | 36,331 | $0.00 | - | |
| ||||||
| John Kiely - Director | Open-market sale | Class A Common Stock | 32,000 | $9.23 | $295K | |
| Nikita Shah - Officer | Open-market sale | Class A Common Stock | 114,492 | $9.66 | $1.11M | |
| Nikita Shah - Officer | Open-market sale | Class A Common Stock | 6,340 | $9.50 | $60K | |
| Andrew S. Boyer - Officer | Option exercise | Class A Common Stock | 175,000 | $2.75 | $481K | |
| Andrew S. Boyer - Officer | Open-market sale | Class A Common Stock | 279,244 | $9.38 | $2.62M | |
| Andrew S. Boyer - Officer | Option exercise | Stock Option | 175,000 | $0.00 | - | |
| Nikita Shah - Officer | Open-market sale | Class A Common Stock | 71,694 | $9.29 | $666K | |
| Tasos Konidaris - Officer | Open-market sale | Class A Common Stock | 161,365 | $9.22 | $1.49M | |
| Tasos Konidaris - Officer | Open-market sale | Class A Common Stock | 119,206 | $9.30 | $1.11M | |
| Tasos Konidaris - Officer | Open-market sale | Class A Common Stock | 219,159 | $9.43 | $2.07M | |
| Nikita Shah - Officer | Open-market sale | Class A Common Stock | 50,000 | $9.04 | $452K | |
| Jason B. Daly - Officer | Open-market sale | Class A Common Stock | 22,000 | $9.05 | $199K | |
| Andrew S. Boyer - Officer | Open-market sale | Class A Common Stock | 33,436 | $9.05 | $303K | |
| J. Kevin Buchi - Director | Option exercise | Class A Common Stock | 40,258 | - | - | |
| J. Kevin Buchi - Director | Option exercise | Restricted Stock Units | 40,258 | $0.00 | - | |
| J. Kevin Buchi - Director | Grant or award | Restricted Stock Units | 34,819 | $0.00 | - | |
| Paul M. Meister - Director | Option exercise | Class A Common Stock | 56,361 | - | - | |
| Paul M. Meister - Director | Option exercise | Restricted Stock Units | 56,361 | $0.00 | - | |
| Paul M. Meister - Director | Grant or award | Restricted Stock Units | 48,747 | $0.00 | - | |
| John Kiely - Director | Option exercise | Class A Common Stock | 28,506 | $4.76 | $136K | |
| John Kiely - Director | Open-market sale | Class A Common Stock | 17,058 | $8.38 | $143K | |
| John Kiely - Director | Option exercise | Stock Option | 28,506 | $0.00 | - | |
| Deborah M. Autor - Director | Open-market sale | Class A Common Stock | 6,771 | $8.41 | $57K | |
| Deborah M. Autor - Director | Open-market sale | Class A Common Stock | 33,229 | $8.34 | $277K | |
| Jason B. Daly - Officer | Open-market sale | Class A Common Stock | 13,665 | $8.40 | $115K | |
| Jason B. Daly - Officer | Open-market sale | Class A Common Stock | 43,657 | $8.61 | $376K | |
Item 1.01, 2.01, 2.03, 3.02, 7.01, 9.01
Item 1.01
Item 5.07
Item 2.02, 7.01, 9.01
Recent AMRX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| JOHN KIELY | Director | 50,000 | $880K | View on EDGAR | |
| NIKITA SHAH | Officer | 146,403 | $2.56M |
AMRX insider trading FAQ
What is the latest insider trade for AMRX?
Amneal Pharmaceuticals, Inc. (AMRX) had 12 insider filings in the last 90 days, with the most recent on 2026-09-21. The full record for AMRX runs to 51 Form 4 filings, the earliest from 2024-11-19. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AMRX stock?
No insider purchases of AMRX were filed in the last 90 days.
How many insiders are selling AMRX stock?
4 insider sales of AMRX were filed in the last 90 days, totaling $7.22M.
Where can I see AMRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AMRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - J. Kevin Buchi view on EDGAR
- - J. Kevin Buchi view on EDGAR
- - Andrew S. Boyer view on EDGAR
- - Andrew S. Boyer view on EDGAR
- - John Kiely view on EDGAR
- - Nikita Shah view on EDGAR
- - Jason B. Daly view on EDGAR
- - J. Kevin Buchi view on EDGAR
- - Tushar Bhikhubhai Patel view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where AMRX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AMRX with a 7-day demo
- AMRX on your watchlist
- Every AMRX Form 4 filing on record
- Up to 3 months of AMRX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
